{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:22:09Z","timestamp":1773087729539,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.rdc.2023.01.008","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T08:08:18Z","timestamp":1677658098000},"page":"337-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of Inflammatory Arthritis in Systemic Sclerosis"],"prefix":"10.1016","volume":"49","author":[{"given":"Cristiane","family":"Kayser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Vict\u00f3ria de Oliveira Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rdc.2023.01.008_bib1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.autrev.2012.06.004","article-title":"Overlap connective tissue disease syndromes","volume":"12","author":"Iaccarino","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.008_bib2","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3899\/jrheum.091165","article-title":"Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database","volume":"37","author":"Avouac","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2023.01.008_bib3","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/rheumatology\/kes041","article-title":"Articular involvement in systemic sclerosis","volume":"51","author":"Avouac","year":"2012","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.008_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2397198318779532","article-title":"Inflammatory arthritis in systemic sclerosis: what to do?","volume":"4","author":"Blank","year":"2019","journal-title":"J\u00a0Scleroderma Relat Disord"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.008_bib5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/03009740410006060","article-title":"Daily activities and hand function in women with scleroderma","volume":"33","author":"Sandqvist","year":"2004","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.008_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/ard.41.2.147","article-title":"The articular manifestations of progressive systemic sclerosis (scleroderma)","volume":"41","author":"Baron","year":"1982","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2023.01.008_bib7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.rdc.2015.04.011","article-title":"Musculoskeletal manifestations of systemic sclerosis","volume":"41","author":"Morrisroe","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"issue":"11","key":"10.1016\/j.rdc.2023.01.008_bib8","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.autrev.2013.05.002","article-title":"Systemic sclerosis at the crossroad of polyautoimmunity","volume":"12","author":"Elhai","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.rdc.2023.01.008_bib9","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.2005.044602","article-title":"Radiological hand involvement in systemic sclerosis","volume":"65","author":"Avouac","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2023.01.008_bib10","first-page":"542","article-title":"Anti-cyclic citrullinated peptide antibody in systemic sclerosis","volume":"26","author":"Morita","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2023.01.008_bib11","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3899\/jrheum.101248","article-title":"Clinical and serological hallmarks of systemic sclerosis overlap syndromes","volume":"38","author":"Pakozdi","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2023.01.008_bib12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s10067-011-1930-z","article-title":"Anti-cyclic citrullinated peptide antibodies in scleroderma patients","volume":"31","author":"Polimeni","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2023.01.008_bib13","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/rheumatology\/keq205","article-title":"Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis","volume":"49","author":"Ueda-Hayakawa","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2023.01.008_bib14","doi-asserted-by":"crossref","first-page":"151947","DOI":"10.1016\/j.semarthrit.2021.11.013","article-title":"Erosive arthritis autoantibodies in systemic sclerosis","volume":"52","author":"Riccardi","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.008_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2023.01.008_bib16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.rdc.2013.02.017","article-title":"Imaging of Scleroderma","volume":"39","author":"Chapin","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"issue":"8","key":"10.1016\/j.rdc.2023.01.008_bib17","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/acr.21668","article-title":"Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings","volume":"64","author":"Elhai","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"8","key":"10.1016\/j.rdc.2023.01.008_bib18","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00296-013-2665-8","article-title":"Magnetic resonance imaging versus musculoskeletal ultrasonography in detecting inflammatory arthropathy in systemic sclerosis patients with hand arthralgia","volume":"33","author":"Abdel-Magied","year":"2013","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.rdc.2023.01.008_bib19","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/rheumatology\/kew246","article-title":"Validation of disease activity indices using the 28 joint counts in systemic sclerosis","volume":"55","author":"L\u00f3r\u00e1nd","year":"2016","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.rdc.2023.01.008_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/BOR.0000000000000711","article-title":"Management of systemic sclerosis: the first five years","volume":"32","author":"Roofeh","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.008_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-01844-y","article-title":"French recommendations for the management of systemic sclerosis","volume":"16","author":"Hachulla","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"10.1016\/j.rdc.2023.01.008_bib22","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.008_bib23","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.008_bib24","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.008_bib25","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.semarthrit.2019.12.004","article-title":"Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience","volume":"50","author":"Castellv\u00ed","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.008_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase ii investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2023.01.008_bib27","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.008_bib28","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.008_bib29","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/1756-185X.14333","article-title":"Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: a case series study and review of the literature","volume":"25","author":"Yarkan Tu\u011fsal","year":"2022","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.008_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3899\/jrheum.100361","article-title":"Biologic therapy for systemic sclerosis: a systematic review","volume":"38","author":"Phumethum","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.008_bib31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.008_bib32","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2147\/DDDT.S204730","article-title":"Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?","volume":"13","author":"Huang","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"10.1016\/j.rdc.2023.01.008_bib33","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00296-021-04956-7","article-title":"Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound","volume":"41","author":"Karalilova","year":"2021","journal-title":"Rheumatol Int"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.008_bib34","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/ard.2006.060111","article-title":"Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: A pilot study","volume":"66","author":"Nacci","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2023.01.008_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101707","article-title":"A\u00a0comprehensive framework for navigating patient care in systemic sclerosis: a global response to the need for improving the practice of diagnostic and preventive strategies in SSc","volume":"35","author":"Saketkoo","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.008_bib36","doi-asserted-by":"crossref","first-page":"rkz044","DOI":"10.1093\/rap\/rkz044","article-title":"The effect and safety of exercise therapy in patients with systemic sclerosis: a systematic review","volume":"3","author":"Liem","year":"2019","journal-title":"Rheumatol Adv Pract"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X2300008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X2300008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:31:40Z","timestamp":1760182300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X2300008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0889857X2300008X"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2023.01.008","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Inflammatory Arthritis in Systemic Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2023.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}